Albumax has been approved under code B4155 as an enteral product. This approval allows for Medicaid reimbursement of costs for eligible patients using Albumax. Albumax has previously received approval from the New York State Medicaid Office.
It is reported that Medicaid is the largest source of funding for medical and health-related services for people with limited income. It is an entitlement program that is jointly funded by the states and federal government, and is managed by the states. Among the groups of people served by Medicaid are eligible low-income parents, children, seniors and people with disabilities.
Dino Luzzi, CEO of Medivisor, said: “These additional Medicaid approvals are extremely important for the national rollout of Albumax. Medicaid acceptance for Albumax increases the willingness of providers and patients to use Albumax to increase blood albumin levels in kidney disorder patients.”